Agile Therapeutics, Inc. AGRX
Aug 22, 2024, 3:58 PM EDT
52-week range unavailable
- Market cap
- 889.10K
- Revenue (ttm)
- 19.98M
- Profit margin
- -69.72%
- Shares out
- 2.96M
- Forward P/E
- 0.27
- Volume
- 119.29K
- Open
- 1.48
- Previous close
- 1.51
- Day's range
- 1.44 – 1.51
- Beta
- 1.50
- Analysts
- Hold
- Price target
- 5.00 (+231.1%)
- Earnings date
- Aug 12, 2024
2Y -19.69 (-92.88%)
Key statistics
- Enterprise value
- 573.31K
- PEG ratio
- 0.00
- Price / sales
- 0.04
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 121.90%
- Free cash flow
- -4.36M
- Total cash
- 2.87M
- Total debt
- 2.52M
- Return on equity
- 0.00%
- Short % of float
- 7.50%
- 50-day average
- 0.91428
- 200-day average
- 1.89
Analyst view
Consensus: hold
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.51.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -3.48 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 21, 2023 | Maxim Group | up | Hold | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 6, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Agile Therapeutics, Inc.
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
- Country
- United States
- Website
- agiletherapeutics.com
News
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L. 
Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World: 2-Day Training Course (Online) November 18-19, 2024 - Become Competent and Familiar in a Range of Well-Recognised Leadership Techniques 
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX 
AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders 
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L. 
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update 
Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript 
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update 
Agile Therapeutics Announces Delisting from Nasdaq 
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
Your note
Sign in to keep a note on AGRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTOMARI ALFRED | Chief Executive Officer | Stock Award(Grant) | Jun 27, 2023 | 47,749 |
| BARBARI SHARON SURREY A | Director | Stock Award(Grant) | Jun 7, 2023 | 974 |
| CARSON SANDRA | Director | Stock Award(Grant) | Jun 7, 2023 | 974 |
| COIANTE SCOTT M | Chief Financial Officer | Stock Award(Grant) | Oct 2, 2023 | 20,080 |
| CONWAY ROBERT G. | Officer | Stock Award(Grant) | Jun 27, 2023 | 13,529 |
| FISCHER SETH H Z | Director | Stock Award(Grant) | Jun 7, 2023 | 976 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 6.33% | 122,000 | 359.90K | Jun 29, 2023 |
| State Street Corporation | 0.56% | 10,843 | 31.99K | Jun 29, 2023 |
| Blackrock Inc. | 0.31% | 6,061 | 17.88K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.14% | 2,712 | 8.00K | Jun 29, 2023 |
| Investor AB | 0.09% | 1,754 | 5.17K | Jun 29, 2023 |
| Royal Bank of Canada | 0.04% | 758 | 2.24K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.21% | 4,098 | 15.53K | May 30, 2023 |
| Vanguard Extended Market Index Fund | 0.20% | 3,765 | 11.11K | Jun 29, 2023 |
| Fidelity Series Total Market Index Fund | 0.03% | 502 | 1.90K | May 30, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.02% | 295 | 767 | Aug 30, 2023 |